Crizotinib, a TKI for which we have shown promising in vitro results for the treatment of GC presenting MET amplification/overactivation, is already in clinical setting for the treatment of EML4-ALK–translocated (ALK-positive) non-small cell lung cancer (NSCLC) patients. This evidence concerns the gene MET and non-small cell lung carcinoma.